Hims & Hers Strikes Novo Nordisk Deal, Shares Jump 48% on Weight-Loss Tie-Up
Hims & Hers resolved its patent lawsuit with Novo Nordisk, securing a deal to distribute Novo’s semaglutide-based weight-loss drugs on its telehealth platform. The company posted Q4 revenue of $617.8 million and EPS of $0.08, beating estimates, but issued Q1 guidance of $600–625 million below analyst forecasts.
1. Legal Feud Ends and Partnership Details
Hims & Hers Health ended its patent infringement lawsuit with Novo Nordisk, clearing the way for Novo’s weight-loss semaglutide products to be offered on Hims & Hers’ telehealth platform. This resolves longstanding disputes over compounded versions and establishes a revenue-sharing arrangement for direct-to-consumer drug distribution.
2. Q4 Earnings and Guidance
In the fourth quarter, the company reported $617.82 million in revenue, narrowly missing analyst projections of $619.22 million, while EPS reached $0.08 versus estimates of $0.03. Management forecasted first-quarter revenue of $600–625 million and full-year sales of $2.7–2.9 billion, both below consensus figures.
3. Stock Reaction and Technical Outlook
Shares surged 48.67% in premarket trading to $23.40, reflecting market enthusiasm for the partnership. Technical indicators show the stock trading above its 20-day moving average but below its 100-day average, with momentum metrics suggesting potential for further gains.